Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- NIBIO Initiates Support for Applied Research on 15 Promising Drug Seeds with Goal of First Licensing Agreement by FY2015
July 30, 2014
- MHLW to Review Criteria for Clinical Research Core Hospitals by April
July 29, 2014
- Revised PAL Mandating Submission of Package Inserts to Minister Will Take Effect on Nov 25
July 29, 2014
- Govt Thought TPP Talks Would Be Wrapped Up Sooner: Official
July 29, 2014
- PAFSC’s Second Committee to Discuss Kyowa Kirin’s Long-Acting G-CSF Drug Pegfilgrastim on August 8
July 29, 2014
- Editor’s Pick: Five Healthcare News Headlines for July14 - July 25
July 28, 2014
- Health Minister Calls for Strict Compliance with Transparency Guidelines
July 28, 2014
- Japan OKs Guidelines for FY2015 Budget Requests, Natural Rise of 830 Billion Yen in Social Security Costs
July 28, 2014
- PDMA to Issue Practical Notification on Submission of Electronic Applications for Approval Next January at Earliest
July 28, 2014
- MHLW Suggests Regulation for Research Likely to Be Used in Ads
July 25, 2014
- Cabinet Approves Health, Medical Strategy
July 24, 2014
- Toshihiko Takeda Appointed Councilor in Charge of Health Insurance
July 24, 2014
- PMDA Reviewing Infliximab for Risk of Rhabdomyolysis
July 24, 2014
- PAFSC’s First Committee to Discuss MSD’s Insomnia Drug on Aug. 1
July 24, 2014
- Ex-Novartis Employee Indicted on Additional Charges, Prosecutors to Wind Up Probe: Reports
July 23, 2014
- Chain Pharmacies’ Drug Price Settlement Rate in June Triples from 2 Years Ago
July 23, 2014
- MHLW FY2015 Budget Request to Center on PM Abe’s Growth Strategy
July 22, 2014
- ICH M7 Guideline Reaches Step 4; MHLW to Issue Notification
July 22, 2014
- Ministry Panel Agrees to Add Kitasato Daiichi Sankyo Vaccine’s Squarekids to Routine Vaccine Program
July 18, 2014
- Post-Shipment Quality Control Testing of Radiopharmaceuticals Would Not Violate GMP: MHLW
July 18, 2014
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…